Abstract | OBJECTIVE: To test the efficacy of a new scoring system to differentiate high-risk hydatidiform mole (H-mole) and initiate early selective postmolar chemotherapy. STUDY DESIGN: RESULTS: None of the 50 cases in the early chemotherapy group progressed to persistent GTT. However, 58.9% in the control group developed GTT with 8.0% drug resistance. Of those receiving salvage therapy in the 21 ultra-high-risk GTT cases resistant to EMA/CO, 10 of 14 (71%) receiving EMA/EP and 4 of 7 (57.1%) receiving TP/TE achieved remission. CONCLUSION: Early postmolar chemotherapy for high-risk H-mole is effective in preventing progression to persistent GTT and treatment failure. Ultra-high-risk GTT should be approached with multimodal treatment, including EMA/EP and TP/TE regimens.
|
Authors | Seung Jo Kim, Young Jeong Na, Sang Geun Jung, Chan Joo Kim, Seog Nyeon Bae, Chan Lee |
Journal | The Journal of reproductive medicine
(J Reprod Med)
Vol. 52
Issue 9
Pg. 819-30
(Sep 2007)
ISSN: 0024-7758 [Print] United States |
PMID | 17939600
(Publication Type: Journal Article)
|
Chemical References |
- Dactinomycin
- Etoposide
- Paclitaxel
- Cisplatin
- Methotrexate
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Case-Control Studies
- Cisplatin
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Humans
- Hydatidiform Mole
(complications, drug therapy, surgery)
- Korea
- Methotrexate
(administration & dosage)
- Middle Aged
- Neoplasm Recurrence, Local
(diagnosis, prevention & control)
- Paclitaxel
(administration & dosage)
- Pregnancy
- Prospective Studies
- Registries
- Retrospective Studies
- Risk Factors
- Salvage Therapy
- Severity of Illness Index
- Uterine Neoplasms
(complications, drug therapy, surgery)
|